Jubilant Pharmova Limited

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about Credit Rating assigned by ICRA Limited to proposed Non-Convertible Debentures worth ₹1,400 crore with a rating of [ICRA]AA+(Stable).

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about the issuance of secured/unsecured, listed, rated, redeemable non-convertible debentures (NCDs) on a private placement basis.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange regarding the outcome of its Board Meeting held on October 12, 2026, where it approved the issuance of up to 80,000 non-convertible debentures on a private placement basis, aggregating up to ₹800 crore, and sought members' authorization for issuance of non-convertible debt securities on a private placement basis.

Jubilant Pharmova Limited

Jubilant Pharmova's Radiopharma business announces investment of CAD 94.5 million to double production capacity of its flagship product, RUBY-FILL, with the Government of Canada providing a financial support of CAD 23.8 million.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has submitted a certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities and substitution of the depository's name as the registered owner.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about General Updates regarding the withholding of final dividend for the financial year 2025-26 due to non-submission of KYC documents by some shareholders.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about General Updates regarding the USFDA inspection of the Jubilant HollisterStier LLC CMO facility at Spokane WA, U.S.A, which has been classified as 'Voluntary Action Indicated (VAI)' by the USFDA.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has received a Show Cause Notice from the Assistant Commissioner of Commercial taxes (Enforcement)-4, Mysore, proposing a demand of GST, interest, and penalty for the Financial Year 2022-2023. The company intends to file a detailed reply with documentary evidence and expects no financial or operational impact.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about Copy of Newspaper Publication - Re-lodgement and KYC Updation, including special window for re-lodgement of transfer request of Physical Shares and KYC Updation and dematerialization of physical share certificates.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about receiving a Show Cause Notice from the Joint Commissioner, CGST Division, Roorkee, proposing demand of GST, Interest and penalty for the Financial Year 2020-21 to 2021-2022.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 26, 2026, and submitted the Exchange a copy of Srutinizers report along with voting results.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has received USFDA approval for its new Isolator-based fill and finish line, Line 3, at its Contract manufacturing facility in Spokane, U.S.A.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has announced the outcome of its postal ballot, where shareholders have approved the re-appointment of Mr. Priyavrat Bhartia as Managing Director and Mr. Arjun Shanker Bhartia as Joint Managing Director, with the requisite majority.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has submitted copies of published unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, to the NSE, as per Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has announced its financial results for the quarter ended June 30, 2026, with revenue of Rs. 2,229 Cr. and EBITDA of Rs. 268 Cr. The company's revenue grew by 17% YoY, driven by solid growth across all business segments, particularly strong in CDMO Sterile Injectables on the back of technology transfer revenues from the new & third line. However, EBITDA margins declined year-on-year, primarily due to the unavailability of high-margin SPECT radiopharmaceutical products in the Radiopharmaceuticals business.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has submitted its unaudited financial results for the quarter ended June 30, 2026, which includes revenue from operations, other income, and expenses.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about a scheduled meeting with institutional investors and analysts on August 13-14, 2026, to discuss Q1'FY27 earnings presentation.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about General Updates - Newspaper advertisements titled 'Notice of 48th Annual General Meeting, E-voting, Record Date and Final Dividend Information'.

Jubilant Pharmova Limited

Jubilant Pharmova Limited has informed the Exchange about General Updates - Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2025-26, if approved by the members at the ensuing AGM